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Upon completion of capsid assembly, the 
pregenome is retrotranscribed (Summers 
and Mason 1982; Bartenschlager and 
Schaller, 1992). The resulting DNA-
containing nucleocapsid then acquires a 
lipoprotein envelope from the host cell 
(Gerelsaikhan et al., 1996).
The HBV capsid, also known as core 
protein or core antigen (HbcAg). This 
protein consist of 183 residue amino acid 
with two domains: the assembly domain 
that forms the contiguous shell, and the 
protamine domain that is responsible for 
RNA packaging (Nasal, 1992). Dimeric 
capsid  spontaneously assembles into 
icosahedral capsids when expressed in 
Introduction
Hepatitis B virus (HBV) causes acute 
and chronic hepatitis, which is an important 
cause of cirrhosis of the liver and 
hepatocellular carcinoma (HCC). In its 
replication cycle, assembly of HBV virion 
begins with polymerization of the core 
protein to enclose a complex of the 3.2-
kilobase RNA pregenome and reverse 
transcriptase (Bartenschlager et al., 1990). 
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Abstract
Core protein of Hepatitis B virus (HBV) play an important role in infection of HBV into the liver cells. Core 
protein is also including in the HBV genome targeting into the nucleus through modulating carboxyl residues by 
phosphorylation. Nuclear localication Signal (NLS) in HBV core protein is inside the virion structure and it must be 
unmasked in order to function, perhaps by phosphorylation. Phosphorylation of of HBV core protein in turn could 
begin to alter capsid conformation. Staurosporine is a natural product originally isolated from bacterium 
Streptomyces staurosporeus. Staurosporine was discovered to have biological activities ranging from anti-fungal to 
 anti-hypertensive.The interest in these activities resulted in a large investigative effort in chemistry and biology and 
the discovery of the potential for anti-cancer treatment. The main biological activity of Staurosporine is the inhibition 
of protein kinases through the prevention of ATP binding to the kinase. In the present study, we have studied the 
intracellular localization of EGFP-Core fusion protein with triple HBV core and SV-40 nuclear localization signal at 
its carboxyl terminal in presence and absence of Staurosporine. We also to study the effect of Staurosporine treatment 
on the intracellular localization of EGFP-Core fusion protein in the hepatocyte cells line of HepG2 cell. Results 
showed that effect of Staurosporine is prevent the   nuclear localization of EGFP-Core fusion protein into nucleus 
through an inhibition of the phosphorylation of core protein. Stauroporine also prevents cell division so that passive 
trapping of core protein is inhibited. 
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heterologous systems (Cohen and 
Richmond, 1982) or from purified protein 
(Wingfield et al., 1995).
The expression of the HBV core protein 
into human hepatocyte cell line has been 
studied by Haryanto and Kann (2006). HBV 
core protein was found to be localized to the 
cytoplasm, nucleus and both compartment. 
It was localized predominantly into the 
nucleus in HuH-7 cells (Haryanto, 2006). 
HBcAg was found to be distributed in both 
the nucleus and the cytoplasm in HBV-
producing hepatocytes and transgenic mice 
(Guidotti et al., 1995). It has also been 
documented that in HbeAg positive 
patients, a nucleus-dominant distribution of 
intrahepatic HBcAg is associated with minor 
hepatitis activity while a cytoplasmic 
distribution of HBcAg is associated with 
chronic active liver disease (Chua et al., 
2003). 
The molecular basis for the shift from 
nuclear distribution and minor disease 
activity to cytoplasmic distribution and 
disease exacerbation has been unclear. 
Frequent mutations have been found to 
accumulate in HBV core protein during 
natural infections with HBV. It is tempting to 
hypothesize that naturally occurring HBcAg 
variants contribute to the change in the 
subcellular localization of HBV core protein 
(Chuang et al., 1993; Hosono et al., 1995).
The nuclear localization signal (NLS) of 
HBV core protein is located within the 
carboxy-terminal 34 amino acids, in which 
two sequences (145-ETTVVRRRGRSP-156 
and 172-RRRRSQSSRESQC-183) are 
important for nuclear import (Eckhardt et al., 
1991). The same residues contain four poly-
arginine clusters, of which three, located 
between amino acids 157 to 183, have an 
SPRRR motif. The serine residues, in 
particular the ones penultimate to praline 
are phosphorylated in vivo (Roossinck MJ 
and Siddigqui A, 1987).  Mutant protein in 
which serines in the motif are changed to 
alanine are nonphosphorylated and localize 
to the nucleus regardless of the phase of the 
cell cycle, indicating that phosphorylation 
influences the protein’s nuclear localization 
(Liao and Ou, 1995). 
Staurosporine is a microbial alcaloid 
antibiotic. It has been reported to have 
antifungal and strong hypotensive effects 
(Omura et al., 1977). It also seems that 
Staurosporine is the most potent inhibitor of 
2+ the phospholipid/Ca -dependent protein 
kinase C with an IC  of 2.7 nM regarding the 50
enzyme from rat brain (Tamaoki et al., 1986). 
In compare with other known protein kinase 
C inhibitors such as trifluoperazine, 
chloropronaline and polymyxin B,  
Staurosporine is about 3 orders of 
magnitude more effective. This potent 
inhibitory effect makes the compound very 
valuable in investigating the role of protein 
2+phosphorylation by protein kinase C, Ca  
mobilization by inositol phosphates and 
provides a useful tool for the isolation and 
purification of protein kinase C. It also 
inhibits cAMP- and cGMP-dependent 
protein kinase with Ki -values around 7 nM 
and the protein tyrosine kinase activity of 
v-src p60 with an IC  value of 6.4 nM (Nakano et 50
al., 1987). Therefore, Staurosporine is a very 
potent inhibitor of protein tyrosin kinases as 
well.
Besides direct blocking of protein 
kinases, Staurosporine exhibits strong 
cytotoxic effects on various tumor cell lines 
(Tamaoki et al., 1986) and inhibits platelet 
aggregation (Oka et al., 1986; Schächtele et al., 
1988) with an IC  of 3.4 µM or 11.6 µM, 50
depending on induction of aggregation 
induced by either collagen or ADP, 
respectively. The compound does not 
i n t e r f e r e  w i t h  t h e  b i n d i n g  o f  
phosphatidylserine and phorbol esters to 
protein kinase C suggesting different 
binding sites. Additionally, Staurosporine 
2+does not compete with Ca , histones, DAG 
and ATP (Tamaoki et al., 1986). 
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In the present study, we have studied 
the intracellular localization of EGFP-Core 
fusion protein with triple HBV core and SV-
40 nuclear localization signal (NLS) at its 
carboxyl terminal in presence and absence of 
Staurosporine. We want to know effect of 
Staurosporine treatment on the intracellular 
localization of EGFP-Core fusion protein in 
the hepatocyte cells line of HepG2.  
Materials and Methods
The main materials of this study are 
HBV core fusion protein encoding DNA 
plasmid ,  S t aurospor ine  (S IG MA) ,  
transfection agent Tfx-20 (PROMEGA), 
hepatocyte cell line HepG2 and DMEM 
medium (GIBCO-BRL) and Fetal Calf Serum 
or FCS (GIBCO-BRL).
Design of EGFP-Core Fusion Protein 
Encoding Plasmids 
The recombinant plasmid pEGFP-Core 
with single NLS (design by Haryanto and 
Kann, 2006) was used as original DNA 
plasmid.  The  pEGFP-Core was double 
restriction digested with Ava I  and Apa I 
enzymes. Then the linier plasmid DNA 
fragment was ligated with synthetic 
oligonucleotides, that  be ordered from 
MAGV which encoded additional 3 NLS of 
HBV Core and 3 SV-40. Sequence of 
synthetic oligonucleotides for pEGFP-Core 
3C NLS are:
Sense (129 nucleotides):
5’-CTC GGG AAT CTC AAC CTA GAA GAA GAA 
CTC CCT CGC CTC GCA GAC GCA GAT CTC 
AAT CGC CGC GTC GCC CTA GAA GAA GAA 
CTC CCT CGC CTC GCA GAC GCA GAT CTC 
AAT CGC CGC GTC GCT AGG GCC-3’
Antisense (123 nucleotides): 
5’-CTA GCG ACG CGG CGA TTG AGA TCT GCG 
TCT GCG AGGCGA GGG AGT TCT TCT TCT AGG 
GCG ACG CGG CGA TTG AGA TCT GCG TCT 
GCG AGG CGA GGG AGT TCT TCT TCT AGG 
ACA TTG AGA TTC-3’.
Sequence of syntheti oligonucleotides 
for pEGFP-Core 3 SV-40 NLS are:
Sense (92 nucleotides):
5’-CCG GAA ACT ACT GTT GTT CCT AAG AAG 
AAG AGA AAG GTG CCT AAG AAG AAG AGA 
AAG GTG CCT AAG AAG AAG AAG AGA AAG 
GTG TAG GGG CC-3’
Antisense (81 nucleotides):
5’ C CTA CAC CTT TCT CTT CTT CTT AGG CAC 
CTT TCT CTT CTT CTT AGG CAC CTT TCT CTT 
CTT CTT AGG AAC AAC AGT AGT TT-3’
Each of a pair  synthetic oligonucleotide 
contains the artificial restriction site of 
enzyme Ava I at 5’ and Apa I at 3’ of the 
strands. Before ligation, all of the 
ol igonucleotides were adjusted in 
concentration 1 ìg/ìl.  Then between sense 
and antisense has to be hybridized in order 
to form double strand DNA. The 
Hibridisation was done by mixing  sense 
and antisense DNA. After gently mixed the 
Hibridization tube was incubated on the 
heat block at 95°C for 2 minutes and then 
cooled down slowly at room temperature 
and 4°C in refrigerator.
Preparation of hepatocytec cell line HepG2 
In 24 well plate, HepG2 cells was grown 
onto collagenized cover slips one day before 
transfection. The cell lines were incubated 
over night at 37°C in incubator CO  until 75-2
80% confluent.
Transfection and staurosporine treatment 
All construction of DNA were 
transfected into HepG2 cells .  The 
transfection reaction consist of 5 ìl DNA 
plasmid (200 ng/ml) 5 ml Tfx-20 and 300 ml 
serum free medium. Then it was mixed 
gently and incubated at room temperature 
for 5-10 minutes. While, 24 well plate were 
took out from CO incubator and changed the 2 
10% FCS containing medium with serum 
free medium. 24 well plate was returned to 
the CO incubator and continued the 2  
incubation for the appropriate length of time 
before transfection. Transfection was done, 
by replacing serum free medium with the 
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a different frequency (see table ). EGFP-Core 
fusion proteins are indicated by the green 
fluorescence, nuclear pore complexes are 
depicted as red rings. Studies of intracellular 
localization of HBV core protein indicated 
that different species seem to use different 
mechanisms to localize core proteins to the 
nucleus.  Nuclear localization of HBV core 
protein, which is karyophilic, depend on the 
cell cycle, which enhance during G0/G 
phase but suppressed during the S phase 
(Yeh et al, 1993)
Figure 1. Intracellular Localisation of EGFP-Core 3C 
(up) and EGFP-Core 3 SV-40 NLS (below) in HepG2 
cells without Staurosporine treatment . 
mixture of DNA/Tfx-20 reagent/FCS free 
medium 310 ml per well. The 24 well plate 
was incubated in the CO  incubator at 37 °C 2
for 1 hour. During incubation the 10% FCS 
containing medium was warmed at 37°C in 
the waterbath and the inhibitor protein 
kinase C of Staurosporine in concentration 
40 nM/ml direct added in DMEM medium. 
After 1 hours FCS free medium was replaced 
with the 2 ml /ml Staurosporine containing 
DMEM medium and returned  the well plat 
into the CO incubator until 24-48 hours. 2 
Indirect immunostaining and confocal laser 
microscopy
The transfected cells was immune 
stained with mouse monoclonal antibody 
414 anti NPC (1:500) as primary antibody 
and labeled with secondary antibody anti 
mouse, which marked texas red dye (1:100). 
Then the intracellular localization of EGFP-
Core fusion protein determined under 
confocal laser microscope as described 
before by Haryanto (2006). 
Quantification of intracellular localization
The HBV core fusion protein which 
found localized in the compartment of 
HepG2 cells, was quantified manually using 
confocal laser scann microscope. The 
Amount of HBV core protein that 
distributed in the cytoplasm, nucleus or both 
of cell compartment were quantified in the 
absolute and relative values.
Results dan Discussion
Intracellular localization study of HBV core 
protein as EGFP-Core fusion protein with 
three HBV core NLS (EGFP-Core 3C) and 
three SV-40 NLS (EGFP-Core 3 SV-40)  
without Staurosporine treatment shown in 
figure 1. It indicated that all fusion proteins 
were either found predominantly in the 
cytoplasm (upper row) or in the nucleus 
(middle row) or in rare cases in both 
cytoplasm and nucleus (lower row) but with 
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Figure 2 shown that EGFP-Core 3C and 3 
SV40 NLS fusion proteins localized in the 
cytoplasm (upper row) or in nucleus (lower 
row). The presence of EGFP-Core fusion 
proteins are indicated by the green 
fluorescence. The nuclear pore complexes 
are shown as red rim-like stains.
The mechanism of nuclear localization 
of EGFP-Core fusion protein is imported to 
the nucleus is seems to follow natural HBV 
infection. EGFP-Core fusion protein 
followed an active nuclear import mediated 
by cellular nuclear import factors. For 
interaction with the import factors, the core 
proteins expose a ‘classical’ NLS on the 
surface of fusion protein. The NLS is 
localized within the carboxy-terminal 
domain of the core proteins and within the 
lumen of the EGFP fusion protein capsid. 
The exposure of the NLS on the capsid 
surface thus requires a structural change, 
which is caused by phosphorylation of the 
carboxy-terminus as reported by Rabe et al. 
(2003). The NLS is bound by the adapter 
protein importin a and subsequently by the 
cellular transport receptor importin b. 
Following the established pathway of 
nuclear import, importin b mediates the 
binding to the cytoplasmic fibers of the NPC 
and the transport through the pore into the 
nuclear basket (Pante and Kann 2002).
The HBV core protein of the used isolate 
contains seven phosphorylation sites within 
the C-terminus comprising amino acids 140-
183. One additional phosphorylation site is 
found upstream of the C-terminus in the 
flexible linker region at amino acid 139. The 
degree of phosphorylation, the responsible 
protein kinase, the used phosphorylation 
sites and the time point of phosphorylation 
a r e  n o t  f u l l y  u n d e r s t o o d  y e t .  
Phosphorylation at Serine residue 157 is 
required for pregenome packaging and the 
residues 164 and 170 are essential for 
polymerase activity (Gazina et al., 2000; 
Melegari et al., 2005). Moreover, serine 170 
Both EGFP-Core 3C and EGFP-Core 3 
SV-40 fusion protein found localized 
predominantly into nucleus because they 
have strong NLS that responsible on nuclear 
localization. The macromolecule like EGFP-
Core fusion protein up to 28 nm in diameter 
can enter the nucleus through the central 
canal of nuclear pore complex (NPC) if they 
harbor at least one NLS (Feldherr and Akin, 
1990). Protein must contain the NLS in order 
for it to pass through the central transporter 
channel in signal-mediated protein import. 
The signal consists of predominantly basic 
amino acids appearing in either one 
(monopartite NLS) or two (bipartite NLS) 
short clusters. It has been shown that HBV 
nucleocapsids bind to the NPC, following 
the ‘classical’ pathway of karyophilic 
proteins, which is mediated by the cellular 
proteins importin a and b (karyopherin a 
and b). The exposure of a corresponding 
NLS  on  the  sur face  o f  the  HBV 
nucleocapsids, which is bound by importin 
a, appears to be dependent upon genome 
maturation and/or phosphorylation of the 
core subunits (Kann et al. 1999). 
Figure 2. Localization of EGFP-Core 1C in HuH-7 cells 
treated with Staurosporine
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and/or 172 is phosphorylated in capsids 
from virions (Machida et al., 1991). Some 
phosphorylation at a non-specified site is 
essential for nuclear import of the capsids 
(Kann et al., 1999). However, for entire HBV 
capsids it  is  unclear whether the 
phosphate(s) within the C-terminus is/are 
required to allow NLS-importin a-
interaction or whether phosphorylation 
induces a structural change that leads to the 
exposure of the NLS on the capsid surface. 
Unpublished studies using FITC-BSA-HBV 
capsid NLS conjugates revealed that 
phosphorylation within the NLS inhibits the 
transport capacity of the conjugate. 
However, for the SV-40 tag it was shown that 
a phosphate directly adjacent to the NLS has 
a negative effect on nuclear import while 
phosphorylation at sites further upstream 
enhances NLS function (Jans, 1995; Hübner 
et al., 1997; Jans and Jans, 1994).
In order to analyse the effect of 
phosphorylation on nuclear transport of the 
EGFP-Core fusion proteins, cells were 
treated with a broad-range protein kinase 
inhibitor after transfection. EGFP-core 3C 
was used since this protein shows the 
strongest nuclear localisation thus allowing 
the best differentiation in case that inhibition 
of phosphorylation prevents  nuclear  
import.  As a  control  EGFP-Core 3 SV40 
NLS  was used lacking the C-terminus and 
the phosphorylation sites downstream of 
amino acid 143.
Transient expression revealed that the 
cytoplasmic and the nuclear appearance of 
both fusion proteins looked identical (figure. 
2) to their expression in untreated cells     
(figure.1). In all compartments the 
fluorescences looked condensed in some 
areas being more pronounced in the 
cytoplasm. Despite of low transfection 
efficiency, quantification of nuclear and 
cytoplasmic localisation in different cells 
however showed a dramatically changed 
localization (see tabel) in that the vast 
majority of EGFP-Core fusion proteins were 
found within the cytoplasm. In the table 
clearly showed that without Staurosporine 
treatment EGFP-Core 3C and 3 SV40 NLS 
predominantly localized within the nucleus. 
Staurosporine treatment changed the 
distribution pattern in that the cells 
exclusively show a cytoplasmic localization 
of the EGFP-Core fusion proteins. It 
indicated that only HBV core protein 
phosphorylation site present in both fusion 
proteins is located at amino acid 141. In the 
SV40 Tag NLS no phosphorylation site is 
present. Assuming that the changes in the 
distribution pattern is caused by an inhibited 
phosphorylation of the core protein, one 
must conclude that this site has an essential 
function in the viral life cycle in that its 
phosphorylation is important for allowing 
the NLS function. However, Staurosporine 
may have had additional effects. It prevents 
cell division so that passive trapping of 
proteins is inhibited. The main biological 
activity of Staurosporine is the inhibition of 
protein kinases through the prevention of 
ATP binding to the kinase. This is achieved 
t h r o u g h  t h e  s t r o n g e r  a f f i n i t y  o f  
staurosporine to the ATP-binding site on the 
kinase. 
Table. Distribution of EGFP, EGFP-Core 3C and 
pEGFP-Core 3 SV40 NLS in Staurosporine treated 
HuH-7 cells. 
The mechanism of the inhibition of 
protein kinases by Staurosporine is unclear 
so far. Nakano et al., (1987) state that 
Staurosporine may bind to the catalytic 
domain of serine/threorine- as well as 
tyrosine-kinases. In the presence of ATP, 100 
µM even low Staurosporine concentrations 
v-src (1-8 nM) were capable of inhibiting p60
phosphorylation ruling out a competition of 
both compounds. As a consequence 
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Staurosporine should also inhibi t  
phosphorylation in vivo in the presence of 
physiological ATP concentrations. Herbert 
et al. (1990) showed ATP compete with 3H-
Staurosporine binding to protein kinase C 
with an IC  of ATP, 500 nM in the presence of 50
tritiated inhibitor, 2 nM. He also described 
that  isoquinolinesulfonamides and 
naphtalenesulfonamides, classes of non-
selective protein kinase inhibitors, failed to 
antagonize 3H-Staurosporine binding to 
different protein kinases therefore 
suggesting distinct binding sites.
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